Tracking a new hope for Tough-to-Treat blood cancer patients
NCT ID NCT07391761
Summary
This study aims to see how well the drug elranatamab works for patients in Taiwan with multiple myeloma that has come back or stopped responding to other treatments. It will follow about 30 adults who have already tried at least four other therapies. The goal is to understand how the drug performs in real-world medical settings, not just in controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
Conditions
Explore the condition pages connected to this study.